MetaCap

Evotec (EVO) vs Rezolute (RZLT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Evotec (EVO) has outperformed Rezolute (RZLT) over the past year, losing 55.6% versus a loss of 60.1%. Over five years, RZLT leads with a -26.9% price change compared with -94.4% for EVO. Evotec is the larger company by market cap ($469.1 million vs $465.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EVO-55.56%RZLT-60.12%
+36%-28%-92%
Nov 21, 20251 yearNov 20, 2026
EVO-94.42%RZLT-32.41%
+95%-4%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EVO versus RZLT key metrics
MetricEVORZLT
Share price$1.32$3.92
Market cap$469.11M$465.58M
1-day change-8.97%-6.67%
YTD return-57.14%+66.10%
1-year return-55.56%-60.12%
5-year return-94.44%-26.87%
EPS (TTM)$-0.59$-0.76
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-77.60M
52-week high$3.87$11.17
52-week low$1.32$1.07
Distance from 52-week high-65.89%-64.89%
Analyst consensusbuystrong_buy
Avg. price target upside+237.12%+175.51%
Average volume109.16K1.66M
Shares outstanding355.39M118.77M
Employees4,37963
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Evotec

EVO stock →

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics.

Health Care · Biotechnology: Pharmaceutical Preparations · 4,379 employees

About Rezolute

RZLT stock →

Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI.

Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees

EVO vs RZLT FAQ

Which is bigger, Evotec or Rezolute?

Evotec (EVO) is larger, with a market capitalization of $469.11M compared with $465.58M for Rezolute (RZLT).

Which stock has performed better over the past year, EVO or RZLT?

EVO returned -55.56% over the past 12 months, compared with -60.12% for RZLT (price return, excluding dividends). Past performance does not predict future results.

Are Evotec and Rezolute in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons